No Data
No Data
Koshidaka Holdings: Addition of financial results materials for the fiscal year ending August 2012 (Earnings Conference materials)
Pal Group Holdings hits new high.
Top gainers on the TSE Prime Board include Samty Holdings <187A> and Koshidaka Holdings <2157> among the 36 listed companies. Top losers on the TSE Prime Board include Euglena <2931> and Amuse <4301> among the 11 listed companies. New highs and new lows on the TSE Prime, TSE Standard, and TSE Growth: New Highs, New Lows, New Highs, New Lows, New Highs, New Lows 10/1636111115614 10/155751216513 10/113081214411
Koshidaka Holdings And 2 Other Undiscovered Gems With Strong Fundamentals
List of Conversion Stocks (Part 1) [List of Parabolic Signal Conversion Stocks]
○ List of buy conversion stocks Market Code Stock Name Closing Price SAR Tokyo Main Board <1375> Snow Country Maitake 1028 995 <1890> Toyo Construction 1347 1310 <2157> Koshidaka HD 1133 965 <3064> MRO 2500 2264 <3387> Curiles HD 1128 1106 <4078> Sakai Chemicals 2702 2554 <4097> High Pressure Gases 891 856 <4220> Riken
Stocks with potential based on volume changes such as Fourside.
Closing prices, day-on-day changes, and volumes for various stocks: ARM 5,946,817,023 units, DMS 1,569,521,776 units, ZET 35,017,100 units, Forside 1,852,311,609,800 units, Dawn 2,356,257,154,400 units, Koshidaka HD 1,133,150,294,3500 units, ABEJA 1,930,107,35400 units, Aidma HD 1,602,9211 units.
Stocks that moved the previous day part1 include Shochiku, AeroEdge, Koshidaka HD, etc.
Stock name <Code> 11th closing price ⇒ Previous day comparison Shochiku <9601> 9246 -106925 Financial estimates for the fiscal year ending February 25 have been revised downward. Vitz <4440> 840 +30 Operating profit is expected to increase by 50.6% in the previous period and 19.6% in this period. Part-time Thai <2341> 143 -8 The operating profit for the first half decreased by 98.2%, expanding the decrease rate from 80.3% in the first quarter. Chordia <190A> 296 -38 At the Japan Society of Hematology Academic Meeting, the first-phase clinical trial of the CLK inhibitor CTX-712.
No Data
No Data